Drug Profile
Quercetin - Quercegen Pharmaceuticals
Alternative Names: Q Force; QU995™Latest Information Update: 20 Nov 2023
Price :
$50
*
At a glance
- Originator Beijing Chemical Reagent Factory; Catholic University of the Sacred Heart - Rome; Farr Laboratories LLC; Indiana University School of Medicine; Quercegen Pharmaceuticals; Singapore General Hospital; SRI International; Taiyuan Pharmaceutical Factory; University of Birmingham; University of California at Los Angeles; University of Ulster
- Developer National Institutes of Health (USA); Quercegen Pharmaceuticals; University of Michigan
- Class Flavonoids; Small molecules
- Mechanism of Action Antioxidants; Enzyme inhibitors; Free radical scavengers; Platelet aggregation inhibitors; Prostaglandin synthase stimulants; Protein tyrosine kinase inhibitors; Thromboxane A2 synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic obstructive pulmonary disease
- Discontinued Atherosclerosis; Cancer; Cardiovascular disorders; Prostatitis
Most Recent Events
- 09 Sep 2023 Pharmacodynamics data from the preclinical trial for chronic obstructive pulmonary disease presented at the 33rd Annual Congress of the European Respiratory Society 2023 (ERS-2023)
- 21 Aug 2023 Temple University in collaboration with Quercegen Pharmaceuticals, NIH and National center for complementary and integrative health (NCCIH) plans a phase II trial for Chronic obstructive pulmonary disease in USA (PO) in September 2023 (NCT06003270)
- 13 May 2022 Pharmacodynamics data from a preclinical trial presented at the 118th International Conference of the American Thoracic Society (ATS-2022)